Payment overview · 2025
General Payments
$964.47
40 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Anthony Russo, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · COXSACKIE, NY · NPI 1902804412
Verified facts
What the public records show
CMS Open Payments records show Thomas Anthony Russo, PA received $964.47 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $387.52 | 40.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.46 | 11.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.67 | 10.8% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.19 | 8.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.54 | 6.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.06 | 6.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.06 | 4.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.33 | 4.0% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $23.24 | 2.4% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.64 | 2.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.76 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $964.47 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $323.46 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $247.47 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $242.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.21 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.11 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.73 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.06 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.64 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.64 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 105 |
| Lisinopril | Lisinopril | 293 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 66 |
| Gabapentin | Gabapentin | 271 | 56 |
| Omeprazole | Omeprazole | 245 | 62 |
| Losartan Potassium | Losartan Potassium | 216 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 50 |
| Trazodone Hcl | Trazodone Hcl | 172 | 32 |
| Ozempic | Semaglutide | 171 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 152 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 20 |
| Metformin Hcl | Metformin Hcl | 121 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 39 |
| Famotidine | Famotidine | 114 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 25 |
| Sertraline Hcl | Sertraline Hcl | 105 | 24 |
| Farxiga | Dapagliflozin Propanediol | 104 | 18 |
| Metformin Hcl Er | Metformin Hcl | 96 | 22 |
| Eliquis | Apixaban | 90 | 19 |
| Celecoxib | Celecoxib | 88 | 19 |
| Jardiance | Empagliflozin | 84 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 26 |
| Simvastatin | Simvastatin | 81 | 20 |
| Furosemide | Furosemide | 79 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Alprazolam | Alprazolam | 73 | 24 |
| Carvedilol | Carvedilol | 70 | 12 |
| Potassium Chloride | Potassium Chloride | 68 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 11 |
| Ezetimibe | Ezetimibe | 60 | 14 |
| Buspirone Hcl | Buspirone Hcl | 59 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 15 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Prednisone | Prednisone | 44 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 34 |
| Allopurinol | Allopurinol | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 13 |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $964.47 · 40 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JOURNAVX, Kerendia, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REJOYN, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error